Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo

被引：0
|
作者：
Kirsten Dettmar
Isabell Seitz-Merwald
Carsten Lindemann
Petra Schroeder
Diane Seimetz
Judith Atz
机构：
[1] Fresenius Biotech GmbH,
[2] EUFETS GmbH,undefined
来源：
Clinical and Translational Oncology | 2012年 / 14卷
关键词：
Catumaxomab; Trifunctional antibody; T lymphocyte; Endothelium; Adhesion; Redistributi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：376 / 381
页数：5
相关论文
共 50 条
  • [41] A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease
    van Oosterhout, YVJM
    van Emst, L
    Schattenberg, AVMB
    Tax, WJM
    Ruiter, DJ
    Spits, H
    Nagengast, FM
    Masereeuw, R
    Evers, S
    de Witte, T
    Preijers, FWMB
    BLOOD, 2000, 95 (12) : 3693 - 3701
  • [42] Ligation of CD2 amplifies anti-CD3 x anti-CD28-mediated ex vivo activation and expansion of T cells.
    Grosmaire, L
    Ledbetter, J
    Berenson, R
    Law, CL
    BLOOD, 2000, 96 (11) : 40B - 40B
  • [43] Preservation of murine T cell alloreactivity following ex vivo activation with anti-CD3 and anti-CD28 antibody coated beads.
    Rettig, MP
    DiPersio, JF
    Ritchey, JK
    Nervi, B
    Bonyhadi, ML
    BLOOD, 2003, 102 (11) : 746A - 746A
  • [44] Pentoxifylline inhibits granzyme B and perforin expression following T-lymphocyte activation by anti-CD3 antibody
    Hoskin, DW
    Phu, T
    Makrigiannis, AP
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1996, 18 (11): : 623 - 631
  • [45] INVIVO LYMPHOCYTE-T ACTIVATION INDUCED IN MICE FOLLOWING THE INJECTION OF ANTI-CD3 MONOCLONAL-ANTIBODY
    FERRAN, C
    BLUESTONE, J
    BACH, JF
    CHATENOUD, L
    TRANSPLANTATION PROCEEDINGS, 1990, 22 (04) : 1922 - 1923
  • [46] Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
    Antoniewicz, A. A.
    Albert, F.
    Wessels, F.
    Lenhart, M.
    Neuberger, M.
    Ruf, P.
    Lindhofer, H.
    Oberneder, R.
    Kriegmair, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1160 - S1160
  • [47] Intravesical therapy with the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab is well tolerated and shows encouraging preliminary efficacy in patients with high-risk NMIBC (CATUNIBLA phase I trial).
    Albert, Felix
    Antoniewicz, Aleksander
    Grantzow, Tobias
    Fingerle-Rowson, Guenter
    Ruf, Peter
    Lindhofer, Horst
    Kriegmair, Maximilian
    Oberneder, Ralph
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16555 - E16555
  • [48] Adoptive immunotherapy of p53-mutated B-CLL with a trifunctional antibody (anti-CD3 x anti-CD20) and allogeneic donor lymphocyte transfusion
    Buhmann, R
    Stanglmaier, M
    Simoes, B
    Yang, T
    Ruf, P
    Lindhofer, H
    Kolb, HJ
    BONE MARROW TRANSPLANTATION, 2006, 37 : S226 - S227
  • [49] Adoptive immunotherapy of p53-mutated B-CLL with a trifunctional antibody (anti-CD3 x anti-CD20) and allogeneic donor lymphocyte transfusion
    Buhmann, R
    Stanglmaier, M
    Simoes, B
    Yang, T
    Ruf, P
    Lindhofer, H
    Kolb, HJ
    BLOOD, 2005, 106 (11) : 286B - 286B
  • [50] Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo
    Juan Ma
    Tengfei Shang
    Pan Ma
    Xin Sun
    Jin Zhao
    Ximing Sun
    Man Zhang
    Investigational New Drugs, 2019, 37 : 1036 - 1043
12345